Cargando…

Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling

INTRODUCTION: The colitis induced by trinitrobenzenesulfonic acid (TNBS) is a chronic and systemic inflammatory disease that leads to intestinal barrier dysfunction and autoimmunedisorders. However, the existing treatments of colitis are associated with poor outcomes, and the current strategies rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yaxing, Liu, Peng, Luan, Haofan, Jiang, Hua, Xu, Yingmei, Zhang, Yuanqiang, Zhang, Yubin, Li, Ruiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165096/
https://www.ncbi.nlm.nih.gov/pubmed/37168866
http://dx.doi.org/10.3389/fimmu.2023.1130404
_version_ 1785038196470448128
author Zhao, Yaxing
Liu, Peng
Luan, Haofan
Jiang, Hua
Xu, Yingmei
Zhang, Yuanqiang
Zhang, Yubin
Li, Ruiyan
author_facet Zhao, Yaxing
Liu, Peng
Luan, Haofan
Jiang, Hua
Xu, Yingmei
Zhang, Yuanqiang
Zhang, Yubin
Li, Ruiyan
author_sort Zhao, Yaxing
collection PubMed
description INTRODUCTION: The colitis induced by trinitrobenzenesulfonic acid (TNBS) is a chronic and systemic inflammatory disease that leads to intestinal barrier dysfunction and autoimmunedisorders. However, the existing treatments of colitis are associated with poor outcomes, and the current strategies remain deep and long-time remission and the prevention of complications. Recently, demethyleneberberine (DMB) has been reported to be a potential candidate for the treatment of inflammatory response that relied on multiple pharmacological activities, including anti-oxidation and antiinflammation. However, the target and potential mechanism of DMB in inflammatory response have not been fully elucidated. METHODS: This study employed a TNBS-induced colitis model and acute sepsis mice to screen and identify the potential targets and molecular mechanisms of DMB in vitro and in vivo. The purity and structure of DMB were quantitatively analyzed by high-performance liquid chromatography (HPLC), mass spectrometry (MS), Hydrogen nuclear magnetic resonance spectroscopy ((1)H-NMR), and infrared spectroscopy (IR), respectively. The rats were induced by a rubber hose inserted approximately 8 cm through their anus to be injected with TNBS. Acute sepsis was induced by injection with LPS via the tail vein for 60 h. These animals with inflammation were orally administrated with DMB, berberine (BBR), or curcumin (Curc), respectively. The eukaryotic and prokaryotic expression system of myeloid differentiation protein-2 (MD-2) and its mutants were used to evaluate the target of DMB in inflammatory response. RESLUTS: DMB had two free phenolic hydroxyl groups, and the purity exceeded 99% in HPLC. DMB alleviated colitis and suppressed the activation of TLR4 signaling in TNBS-induced colitis rats and LPS-induced RAW264.7 cells. DMB significantly blocked TLR4 signaling in both an MyD88-dependent and an MyD88-independent manner by embedding into the hydrophobic pocket of the MD-2 protein with non-covalent bonding to phenylalanine at position 76 in a pi–pi T-shaped interaction. DMB rescued mice from sepsis shock induced by LPS through targeting the TLR4–MD-2 complex. CONCLUSION: Taken together, DMB is a promising inhibitor of the MD-2 protein to suppress the hyperactivated TLR4 signaling in inflammatory response.
format Online
Article
Text
id pubmed-10165096
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101650962023-05-09 Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling Zhao, Yaxing Liu, Peng Luan, Haofan Jiang, Hua Xu, Yingmei Zhang, Yuanqiang Zhang, Yubin Li, Ruiyan Front Immunol Immunology INTRODUCTION: The colitis induced by trinitrobenzenesulfonic acid (TNBS) is a chronic and systemic inflammatory disease that leads to intestinal barrier dysfunction and autoimmunedisorders. However, the existing treatments of colitis are associated with poor outcomes, and the current strategies remain deep and long-time remission and the prevention of complications. Recently, demethyleneberberine (DMB) has been reported to be a potential candidate for the treatment of inflammatory response that relied on multiple pharmacological activities, including anti-oxidation and antiinflammation. However, the target and potential mechanism of DMB in inflammatory response have not been fully elucidated. METHODS: This study employed a TNBS-induced colitis model and acute sepsis mice to screen and identify the potential targets and molecular mechanisms of DMB in vitro and in vivo. The purity and structure of DMB were quantitatively analyzed by high-performance liquid chromatography (HPLC), mass spectrometry (MS), Hydrogen nuclear magnetic resonance spectroscopy ((1)H-NMR), and infrared spectroscopy (IR), respectively. The rats were induced by a rubber hose inserted approximately 8 cm through their anus to be injected with TNBS. Acute sepsis was induced by injection with LPS via the tail vein for 60 h. These animals with inflammation were orally administrated with DMB, berberine (BBR), or curcumin (Curc), respectively. The eukaryotic and prokaryotic expression system of myeloid differentiation protein-2 (MD-2) and its mutants were used to evaluate the target of DMB in inflammatory response. RESLUTS: DMB had two free phenolic hydroxyl groups, and the purity exceeded 99% in HPLC. DMB alleviated colitis and suppressed the activation of TLR4 signaling in TNBS-induced colitis rats and LPS-induced RAW264.7 cells. DMB significantly blocked TLR4 signaling in both an MyD88-dependent and an MyD88-independent manner by embedding into the hydrophobic pocket of the MD-2 protein with non-covalent bonding to phenylalanine at position 76 in a pi–pi T-shaped interaction. DMB rescued mice from sepsis shock induced by LPS through targeting the TLR4–MD-2 complex. CONCLUSION: Taken together, DMB is a promising inhibitor of the MD-2 protein to suppress the hyperactivated TLR4 signaling in inflammatory response. Frontiers Media S.A. 2023-04-24 /pmc/articles/PMC10165096/ /pubmed/37168866 http://dx.doi.org/10.3389/fimmu.2023.1130404 Text en Copyright © 2023 Zhao, Liu, Luan, Jiang, Xu, Zhang, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhao, Yaxing
Liu, Peng
Luan, Haofan
Jiang, Hua
Xu, Yingmei
Zhang, Yuanqiang
Zhang, Yubin
Li, Ruiyan
Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title_full Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title_fullStr Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title_full_unstemmed Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title_short Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
title_sort demethyleneberberine alleviated the inflammatory response by targeting md-2 to inhibit the tlr4 signaling
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165096/
https://www.ncbi.nlm.nih.gov/pubmed/37168866
http://dx.doi.org/10.3389/fimmu.2023.1130404
work_keys_str_mv AT zhaoyaxing demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT liupeng demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT luanhaofan demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT jianghua demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT xuyingmei demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT zhangyuanqiang demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT zhangyubin demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling
AT liruiyan demethyleneberberinealleviatedtheinflammatoryresponsebytargetingmd2toinhibitthetlr4signaling